| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment
|
Wang, Lingling
|
|
|
8 |
2 |
p. 470-481
|
artikel
|
| 2 |
An immunocompetent model to uncover the secrets of bispecifics
|
Maakaron, Joseph E.
|
|
|
8 |
2 |
p. 482-483
|
artikel
|
| 3 |
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
|
Cai, Sheng F.
|
|
|
8 |
2 |
p. 429-440
|
artikel
|
| 4 |
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
|
Ghesquières, Hervé
|
|
|
8 |
2 |
p. 296-308
|
artikel
|
| 5 |
Checkpoints: roadblocks or repairs for the CAR-T journey?
|
Crombie, Jennifer L.
|
|
|
8 |
2 |
p. 468-469
|
artikel
|
| 6 |
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma
|
Choe, Jee H.
|
|
|
8 |
2 |
p. 484-496
|
artikel
|
| 7 |
CT-001, a novel fast-clearing factor VIIa, enhanced the hemostatic activity in postpartum samples
|
Sim, Derek S.
|
|
|
8 |
2 |
p. 287-295
|
artikel
|
| 8 |
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
|
Spencer, Andrew
|
|
|
8 |
2 |
p. 388-398
|
artikel
|
| 9 |
Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
|
Fischer, Kathelijn
|
|
|
8 |
2 |
p. 369-377
|
artikel
|
| 10 |
Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies
|
Baguet, Clémentine
|
|
|
8 |
2 |
p. 337-342
|
artikel
|
| 11 |
Gender disparities in allograft access due to HLA-sensitization in multiparous women
|
Fingrut, Warren B.
|
|
|
8 |
2 |
p. 403-406
|
artikel
|
| 12 |
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy
|
Yu, Kai
|
|
|
8 |
2 |
p. 497-511
|
artikel
|
| 13 |
Increased age-associated B cells in patients with acquired aplastic anemia correlate with IFN-γ
|
Solomou, Elena E.
|
|
|
8 |
2 |
p. 399-402
|
artikel
|
| 14 |
Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study
|
Bader, Peter
|
|
|
8 |
2 |
p. 416-428
|
artikel
|
| 15 |
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
|
Jerkeman, Mats
|
|
|
8 |
2 |
p. 407-415
|
artikel
|
| 16 |
Myers G, Wang Y, Wang Q, et al. Murine erythroid differentiation kinetics in vivo under normal and anemic stress conditions. Blood Adv. 2023;7(19):5727-5732.
|
|
|
|
8 |
2 |
p. 336
|
artikel
|
| 17 |
Natural history of albuminuria in a large cohort of children and adolescents with sickle cell anemia from Brazil
|
Belisário, André Rolim
|
|
|
8 |
2 |
p. 365-368
|
artikel
|
| 18 |
Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior
|
Wang, Siao-Yi
|
|
|
8 |
2 |
p. 324-335
|
artikel
|
| 19 |
Oxygen gradient ektacytometry–derived biomarkers are associated with acute complications in sickle cell disease
|
Rab, Minke A. E.
|
|
|
8 |
2 |
p. 276-286
|
artikel
|
| 20 |
Pharmacological profiling of a berbamine derivative for lymphoma treatment
|
Xu, Senlin
|
|
|
8 |
2 |
p. 309-323
|
artikel
|
| 21 |
Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial
|
Iyer, Swaminathan P.
|
|
|
8 |
2 |
p. 353-364
|
artikel
|
| 22 |
Protein S antibody as an adjunct therapy for hemophilia B
|
Wilson, Hope P.
|
|
|
8 |
2 |
p. 441-452
|
artikel
|
| 23 |
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
|
Hill, Brian T.
|
|
|
8 |
2 |
p. 378-387
|
artikel
|
| 24 |
Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia
|
Lin, Tasha L.
|
|
|
8 |
2 |
p. 261-275
|
artikel
|
| 25 |
Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
|
Hirayama, Alexandre V.
|
|
|
8 |
2 |
p. 453-467
|
artikel
|
| 26 |
Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML
|
Jimenez-Chillon, Carlos
|
|
|
8 |
2 |
p. 343-352
|
artikel
|
Tijdschrift beschrijving